Evidence map›Paper›PMID 33083651›Full record

ArticleAdvances in radiation oncology

Survey of Radiation Oncologists to Assess Interest and Potential Use of a Genetic Test Predicting Susceptibility for the Development of Toxicities After Prostate Cancer Radiation Therapy.

Kayla Collado, Sarah L Kerns, Michael A Diefenbach, Elizabeth Peterson-Roth, Raymond Koski, Harry Ostrer, Richard G Stock, Martin Mattessich, Paul Kaplan, Barry S Rosenstein

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kayla ColladoDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Sarah L KernsUniversity of Rochester Medical Center, Rochester, New York.
Michael A DiefenbachNorthwell Health, Manhasset, New York.
Elizabeth Peterson-RothL2 Diagnostics, LLC, New Haven, Connecticut.
Raymond KoskiL2 Diagnostics, LLC, New Haven, Connecticut.
Harry OstrerAlbert Einstein College of Medicine, New York, New York.
Richard G StockDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Martin MattessichL2 Diagnostics, LLC, New Haven, Connecticut.
Paul KaplanL2 Diagnostics, LLC, New Haven, Connecticut.
Barry S RosensteinDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Icahn School of Medicine at Mount Sinai · USAlbert Einstein College of Medicine · USNorthwell Health · USUniversity of Rochester Medical Center · US

Funding

NCI NIH HHS HHSN261201700033C
6 · The paper itself

Abstract

purposeA genetic test predicting susceptibility for the development of toxicities after prostate cancer radiation therapy is in development. This test intends to help physicians with treatment decision making. METHODS AND MATERIALS: Radiation oncologists were surveyed using a web-based questionnaire to gauge their interest in using a genetic test predictive of increased risk of radiation therapy toxicities as an aid in determining therapy for men with prostate cancer. Responses were summarized using frequencies, and a χ

resultsAmong 204 radiation oncologists (64% from the United States, 36% from other countries), 86.3% would order a genetic test and 80.2% said the test would be useful for treatment discussions. There was wide acceptance (76.7%) to offer a genetic test to all patients considering radiation therapy for prostate cancer. Additionally, 98.1% indicated that patients would be receptive to the test information. There were no significant differences in the likelihood of ordering a genetic test based on practice setting, familiarity with scientific literature, time spent on research, or geographic location (all

conclusionsRadiation oncologists who treat prostate cancer are interested in and willing to order a genetic test predictive of susceptibility to radiation therapy toxicity to aid their treatment decision making.

Identifiers

PMID33083651
PMCPMC7557145
OpenAlexW3016284970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.